Krystle Vermes

The FDA has approved Lundbeck's Carnexiv, also known as carbamazepine, as a short-term (≤7 days) intravenous replacement treatment for adults with certain seizure types who cannot take the oral form of carbamazepine.

The FDA has approved Amjevita, also known as adalimumab-atto, as a biosimilar to Humira.

Ilaris is the first FDA-approved biologic treatment for Tumor Necrosis Factor–Receptor Associated Periodic Syndrome, Hyperimmunoglobulin D Syndrome/Mevalonate Kinase Deficiency and Familial Mediterranean Fever.

Ilaris is the first FDA-approved biologic treatment for Tumor Necrosis Factor–Receptor Associated Periodic Syndrome.

Novartis has received 3 FDA approvals for the expanded use of Ilaris, also known as canakinumab, to treat distinct types of Periodic Fever Syndromes.

QS/1 has released an interface from its workflow process to the eNGAGE patient management platform.

Biologic drug tocilizumab is available in both intravenous and subcutaneous formulations for the treatment of patients with autoimmune conditions.

Actemra/RoActemra (tocilizumab) approved for giant cell arteritis.

The FDA has granted Breakthrough Therapy Designation status to Roche's Actemra/RoActemra, also known as tocilizumab, for the treatment of giant cell arteritis.

Unexpired lots of micron filters may be missing a filter-support membrane and potentially contain particulate matter.

Baxter has voluntarily recalled all unexpired lots of 50-mm 0.2-micron filters with the product code H93835.

Metformin hydrochloride extended-release tablets are the generic version of Fortamet, which improves glycemic control in type 2 diabetes mellitus.

Mylan has launched metformin hydrochloride extended-release tablets, the generic version of Watson's Fortamet, in 500 mg and 1000 mg doses.

Continuous glucose monitoring system provides health care professionals with clear, visual snapshots of glucose levels.

The FDA has approved a new continuous glucose monitoring (CGM) system designed to provide health care professionals with clear, visual snapshots of glucose levels, trends, and patterns in patients with diabetes at a lower cost than other CGM devices on the market.

Brexpiprazole (Rexulti) clinical data supports the use as a maintenance treatment for schizophrenia in adults.

Lundbeck and Otsuka have received FDA approval to update the label of brexpiprazole (Rexulti) with clinical data supporting the drug's use as a maintenance treatment for schizophrenia in adults.

Generic abacavir and lamivudine (Epzicom) tablets are indicated for the treatment of HIV-1 infection in combination with other antiretroviral medicines.

Stelara is the first biologic approved for Crohn’s disease targeting cytokines that play a key role in inflammatory and immune responses.

Teva has launched the generic equivalent of abacavir and lamivudine (Epzicom) tablets in the United States.

Stelara is the first biologic approved for Crohn’s disease targeting interleukin (IL)-12 and IL-23 cytokines, which play a key role in inflammatory and immune responses.

Oral formulation of methylnaltrexone bromide available for adults with chronic noncancer pain.

The FDA recently approved Janssen's ustekinumab (Stelara) for the treatment of moderate to severe active Crohn's disease in adults who have failed or were intolerant to treatment with immunomodulators or corticosteroids but never failed treatment with a tumor necrosis factor (TNF) blocker, as well as those who failed or were intolerant to treatment with one or more TNF blockers.

Valeant and Progenics Pharmaceuticals have just launched an oral formulation of methylnaltrexone bromide (Relistor) in the United States.

Amneal Pharmaceuticals will begin shipping Yuvafem, the first generic equivalent of Novo Nordisk's Vagifem, this October.

Memantine and donepezil hydrochlorides (Namzaric) extended-release capsules in four dosage strenghts are now available by prescription at US pharmacies.

All 4 dosage strengths of memantine and donepezil hydrochlorides (Namzaric) extended-release capsules are now available by prescription at US pharmacies.

Novo Nordisk has submitted a supplemental application to the FDA to include data from the 2 phase 3b SWITCH trials in the prescribing information for insulin degludec (Tresiba), a once-daily basal insulin that provides a duration of action beyond 42 hours for patients with type 1 and type 2 diabetes.

The FDA has granted Orphan Drug Designation to Boehringer Ingelheim's nintedanib for the treatment of systemic sclerosis (SSc), also known as scleroderma, including associated interstitial lung disease (SSc-ILD).

The FDA recently approved Aralez Pharmaceuticals' Yosprala, a once-daily, fixed-dose combination of the antiplatelet agent aspirin and the proton pump inhibitor omeprazole.